NCT03346122 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

November 20, 2018

Study Completion Date

November 20, 2018

Conditions

Healthy

Interventions

DRUG

JNJ-64991524 Dose Level 1

Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.

DRUG

JNJ-64991524 Dose Level 2

Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.

DRUG

JNJ-64991524 Dose Level 3

Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.

DRUG

JNJ-64991524 Dose Level 4

Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.

DRUG

JNJ-64991524 Dose Level 5

Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.

DRUG

JNJ-64991524 Dose Level 6

Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.

DRUG

Placebo

Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.

DRUG

JNJ-64991524 Dose Level 7

Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.

DRUG

JNJ-64991524 Dose Level 8

Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.

DRUG

JNJ-64991524 Dose Level 9

Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.

Trial Locations (1)

2060

SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY